Fundraising FoxRQ Bio
8 known investors
Find your way into RQ Bio
Sign up to find every way you can get introduced to RQ Bio
- Your email: who you already know at RQ Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the RQ Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
Investors · 8
How we know: Frazier Life Sciences's portfolio page · biospace.com · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: biospace.com · funding news · Not right? Tell us
How we know: pulse2.com · oxfordscienceenterprises.com · Not right? Tell us
How we know: biospace.com · Not right? Tell us
How we know: biospace.com · funding news · Not right? Tell us
How we know: biospace.com · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$115M disclosed across 1 round · 2026
- $115MSeries AJun 2026 · 5 sources
Frazier Life Sciences (lead), EQT Life Sciences, Forbion, LifeArc Ventures, Monograph, Oxford Science Enterprises, Wellington Management
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does RQ Bio do?
- RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease. It focuses on immunocompromised populations such as newborns, the elderly, and patients with weakened immunity who may not respond well to seasonal vaccines.
- Who are RQ Bio's investors?
- RQ Bio's investors include Frazier Life Sciences, LifeArc Ventures, Oxford Science Enterprises, Wellington Management, EQT Life Sciences, Forbion, Monograph Capital Partners, Red Tree Venture.
- How much funding has RQ Bio raised?
- RQ Bio has disclosed $115M raised across 1 round.